Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes

Korean Journal of Internal Medicine

Volumn 26, Issue 2, 2011, Pages 153-159

  Lee, Jinwoo ^a   Lee, Chang Hoon ^b   Kim, Deog Kyeom ^b   Yoon, Ho Il ^a   Kim, Jae Yeol ^c   Lee, Sang Min ^a   Yang, Seok Chul ^a   Lee, Jae Ho ^a   Yoo, Chul Gyu ^a   Lee, Choon Taek ^a   Chung, Hee Soon ^b   Kim, Young Whan ^a   Han, Sung Koo ^a   Yim, Jae Joon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

Levofloxacin; Moxifloxacin; Multidrug resistant; Quinolones; Tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CREATININE; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; RIFAMPICIN;

ADULT; ALLERGIC REACTION; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; EYE TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OTOTOXICITY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SKIN DISEASE; TREATMENT RESPONSE; TUBERCULOUS LYMPHADENITIS;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; OFLOXACIN; QUINOLINES; RECURRENCE; REMISSION INDUCTION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79959818137     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.2.153     Document Type: Article

References (30)

1. World Health Organization. Multidrug and extensively drug-resistant tuberculosis: 2010 global report on surveillance and response. Geneva: World Health Organization, 2010.
2. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18.
3. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862.
4. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
6. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-442.
7. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782.
8. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999;58 Suppl 2:19-22.
9. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first-and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-1616.
10. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-1481.
11. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751.
12. Hwang SS, Kim HR, Kim HJ, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009;33:581-585.
13. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patient s with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-1295.
14. Kim DK, Park GM, Hwang YI, et al. Microarray analysis of gene expression associated with extrapulmonary dissemination of tuberculosis. Respirology 2006;11:557-565.
15. Kim HJ, Kang CH, Kim YT, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006;28:576-580.
16. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645.
17. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-326.
18. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235.
19. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481.
20. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-985.
21. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
22. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657.
23. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069.
24. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89.
25. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122.
26. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001;7:135-137.
27. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-1344.
28. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582.
29. Flynn JL, Capuano SV, Croix D, et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) 2003;83:116-118.
30. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612.